{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000036","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-06-25T20:02:15+00:00","discovered_at":"2026-06-25T20:03:00.642347+00:00","generated_at":"2026-06-25T20:03:16.917572+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Keros appoints Anne Prener to Board of Directors, effective July 1, 2026","bullets":["Anne Prener, M.D., Ph.D., appointed as Class III director with term expiring at 2029 annual meeting.","Initial equity grants: $150K option and $150K RSU, each vesting quarterly over three years.","Annual compensation: $75K option, $75K RSU, and $41,500 cash retainer for board service.","Dr. Prener brings clinical development leadership; formerly CEO of Imbria, Freeline, Gyroscope, and exec at Baxalta and Novo Nordisk."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000036","json":"https://secwatch.observer/filing/0001664710-26-000036.json","markdown":"https://secwatch.observer/filing/0001664710-26-000036.md","text":"https://secwatch.observer/filing/0001664710-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/0001664710-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000036/kros-20260623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:03:16.917572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}